Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> PFIZER Latest News

FEB 08, 2013 - Benzinga

A Must Read - Share

OxOnc Announces Deal with Pfizer to Develop Crizotinib as First-Line, Second-Line Treatment for Patietns with ROS1-Positive Non-Small Cell Lung Cancer

OxOnc Development LP, (OxOnc), today announced that it has entered into a co-development agreement with Pfizer Inc., to conduct a pivotal clinical trial of Pfizer's (NYSE: PFE) crizotinib, marketed under the trademark Xalkori®, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene rearrangement

Tags: OxOnc Announces Deal with Pfizer to Develop Crizotinib as First-Line, Second-Line Treatment for Patietns with ROS1-Positive Non-Small Cell Lung Cancer,  Pfizer Latest News